XORTX Therapeutics Past Earnings Performance
Past criteria checks 0/6
XORTX Therapeutics's earnings have been declining at an average annual rate of -30.6%, while the Pharmaceuticals industry saw earnings growing at 46% annually.
Key information
-30.6%
Earnings growth rate
-13.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 23.1% |
| Revenue growth rate | n/a |
| Return on equity | -54.8% |
| Net Margin | n/a |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
No updates
Recent updates
Here's Why We're Watching XORTX Therapeutics' (CVE:XRTX) Cash Burn Situation
Aug 23
XORTX Therapeutics (CVE:XRTX) Is In A Strong Position To Grow Its Business
Apr 01We're Interested To See How XORTX Therapeutics (CVE:XRTX) Uses Its Cash Hoard To Grow
Dec 16Companies Like XORTX Therapeutics (CSE:XRX) Can Afford To Invest In Growth
Sep 01Revenue & Expenses Breakdown
How XORTX Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -1 | 2 | 1 |
| 31 Mar 24 | 0 | -3 | 2 | 1 |
| 31 Dec 23 | 0 | -2 | 2 | 2 |
| 30 Sep 23 | 0 | -7 | 2 | 4 |
| 30 Jun 23 | 0 | -7 | 2 | 5 |
| 31 Mar 23 | 0 | -7 | 2 | 6 |
| 31 Dec 22 | 0 | -8 | 2 | 7 |
| 30 Sep 22 | 0 | 1 | 3 | 5 |
| 30 Jun 22 | 0 | -3 | 2 | 4 |
| 31 Mar 22 | 0 | -2 | 2 | 3 |
| 01 Jan 22 | 0 | -2 | 2 | 1 |
| 30 Sep 21 | 0 | -9 | 1 | 0 |
| 30 Jun 21 | 0 | -3 | 1 | 0 |
| 31 Mar 21 | 0 | -3 | 1 | 0 |
| 31 Dec 20 | 0 | -1 | 1 | 0 |
| 30 Sep 20 | 0 | -1 | 1 | 0 |
| 30 Jun 20 | 0 | -1 | 0 | 0 |
| 31 Mar 20 | 0 | 0 | 0 | 0 |
| 31 Dec 19 | 0 | 0 | 0 | 0 |
| 30 Sep 19 | 0 | 0 | 0 | 0 |
| 30 Jun 19 | 0 | -1 | 0 | 0 |
| 31 Mar 19 | 0 | -1 | 0 | 0 |
| 31 Dec 18 | 0 | -3 | 1 | 0 |
| 30 Sep 18 | 0 | -3 | 1 | 0 |
| 30 Jun 18 | 0 | -3 | 1 | 0 |
| 31 Mar 18 | 0 | -3 | 1 | 0 |
| 31 Dec 17 | 0 | 0 | 0 | 0 |
| 30 Sep 17 | 0 | 0 | 0 | 0 |
| 30 Jun 17 | 0 | 0 | 0 | 0 |
| 31 Mar 17 | 0 | 0 | 0 | 0 |
| 31 Dec 16 | 0 | 0 | 0 | 0 |
Quality Earnings: XRTX is currently unprofitable.
Growing Profit Margin: XRTX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: XRTX is unprofitable, and losses have increased over the past 5 years at a rate of 30.6% per year.
Accelerating Growth: Unable to compare XRTX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: XRTX is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-40.8%).
Return on Equity
High ROE: XRTX has a negative Return on Equity (-54.83%), as it is currently unprofitable.